T. Robak. GA-101, a third-generation, humanized and glycol- engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies. Current Opinion in Investigational Drugs, 2009, 10(6): 588-596.

相关文章:
在线客服:
对外合作:
联系方式:400-6379-560
投诉建议:feedback@hanspub.org
客服号

人工客服,优惠资讯,稿件咨询
公众号

科技前沿与学术知识分享